Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implications for a continuous infusion schedule

Clinical Cancer Research

Volumn 2, Issue 4, 1996, Pages 653-658

  Seymour, John F ^a,b   Huang, Peng ^a   Plunkett, William ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE; FLUDARABINE;

ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; K562 CELLS; VIDARABINE;

EID: 0029989449     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Frei, E., III, Bickers, J. N., Hewlett, J. S., Lang, M., Leary, W. V., and Talley, R. W. Dose, schedule, and antitumor studies of arabinosyl cytosine Cancer Res.. 29: 1325-1332, 1969.
2. Keating, M. J., McCredie, K B., Bodey, G. P., Smith, T. L., Gehan, E. A., and Freireich, E J. Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA, 248: 2481-2486. 1982
3. Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., and Frei, E , III. for the Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med., 331. 896-903, 1994
4. Cassileth, P. A , Lynch, E., Hines, J. D., Oken, M. M., Mazza, J. J., Bennett, S. M., McGlave, P. B., Edelstein, M., Harrington, D. P., and O'Connell, M. J. Varying intensity of postremission therapy in acute myeloid leukemia. Blood, 79: 1924-1930, 1992.
5. Dillman, R. O., Davis, R. B , Green, M. R., Weiss, R. B., Gottlieb, A. J , Caplan, S., Kopel, S., Preisler, H., McIntyre, O. R., and Schiffer, C. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood, 78: 2520-2526, 1991.
6. Chu, M. Y., and Fischer, G. A. Comparative studies of leukemia cells sensitive and resistant to cytosine arabinoside. Biochem. Pharmacol., 14: 333-341, 1965.
7. Schrecker, A. W., and Urshel, M. J. Metabolism of 1-β-D-arabinofuranosylcytosine in leukemia L1210 studies with intact cells. Cancer Res., 28: 793-801, 1968
8. Graham, F. L., and Whitmore, G. F. Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on in-hibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine 5′-triphosphate. Cancer Res., 30: 2636-2644, 1970.
9. Kufe, D. W., Major, P. P., Egan, M., and Beardsley, G. P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem., 255: 8997-9000, 1980.
10. Major, P. P., Egan, E. M., Beardsley, G. P., Minden, M. D., and Kufe, D. W. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc. Natl. Acad. Sci. USA, 78: 3235-3239, 1981.
11. Kufe, D., Spriggs, D., Egan, E. M., and Munroe, D. Relationships among ara-CTP pools, formation of (ara-C)DNA, and cytotoxicity of human leukemic cells. Blood, 64: 54-58, 1984.
12. Spriggs, D., Robbins, G., Ohno, Y., and Kufe, D. Detection of 1-β-D-arabinofuranosylcytosine incorporation into DNA in vivo. Cancer Res., 47. 6532-6536, 1987.
13. Kantarjian, H. M., Estey, E. H., Plunkett, W., Keating, M. J., Walters, R. S., Iacoboni, S., McCredie, K. B., and Freireich, E J. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am. J. Med., 81: 387-394, 1986.
14. Estey, E., Plunkett, W., Dixon, D., Keating, M., McCredie, K., and Freireich, E J. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia (Baltimore), 1: 580-583, 1987.
15. Estey, E. H., Keating, M. J., McCredie, K. B., Freireich, E J, and Plunkett, W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia (Baltimore), 4. 95-99, 1990.
16. 3H]ara-C incorporation and response to therapy with high-dose ara-C in AML patients: a Leukemia Intergroup Study. Exp. Hematol., 20: 1194-1200, 1992.
17. Plunkett, W., and Gandhi, V. Pharmacokinetics of arabinosylcytosine. J. Infusional Chem., 10: 109-114, 1993.
18. Plunkett, W., Gandhi, V., Huang, P., Robertson, L. E., Yang, L-Y., Gregoire, V., Estey, E., and Keating, M. J. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin. Oncol., 20 (Suppl. 7). 2-12, 1993.
19. Grant, S. Biochemical modulation of cytosine arabinoside. Pharmacol. Ther., 48. 29-44, 1990.
20. Gandhi, V., and Plunkett, W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res., 48: 329-334, 1988.
21. Gandhi, V., Estey, E., Keating, M. J., and Plunkett, W. Fludarabine infusion potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol., 11: 116-124, 1993.
22. Gandhi, V., Kemena, A., Keating, M. J., and Plunkett, W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res., 52: 897-903, 1992.
23. Suki, S., Kantarjian, H., Gandhi, V., Estey. E , O'Brien, S., Beran, M., Rios, M. B., Plunkett, W., and Keating, M. J. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer (Phila.), 72: 2155-2160, 1993.
24. Plunkett, W., Liliemark, J. O., Adams, T. M., Nowak, B., Estey, E., Kantarjian, H., and Keating, M. J. Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during highdose 1-′-D-arabinofuranosylcytosine therapy. Cancer Res., 47: 3005-3011, 1987.
25. 2/12 h). Proc. Am. Soc. Clin. Oncol., 5: 164, 1986.
26. Heinemann, V., Estey, E., Keating, M. J., and Plunkett, W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J. Clin. Oncol., 7: 622-628, 1989.
27. Ochs, J., Sinkule, J. A., Danks, M. K., Look, A. T., Bowman, W. P., and Rivera, G. Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia. J. Clin. Oncol., 2: 1092-1097, 1984.
28. Spriggs, D. R., Robbins, G., Arthur, K., Mayer, R. J., and Kufe, D. Prolonged high dose ara-C infusions in acute leukemia. Leukemia (Baltimore), 2: 304-306, 1988.
29. Donehower, R. C., Karp, J. E., and Burke, P. J. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat. Rep., 70: 1059-1065, 1986.
30. Ghaddar, H. M., Plunkett, W., Kantarjian, H. M., Pierce, S., Freireich, E J, Keating, M. J., and Estey, E. Long-term results following treatment of newly diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia (Baltimore), 8: 1269-1274, 1994.
31. Lozzio, C. B., and Lozzio, B. B. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood, 45: 321-334, 1975
32. Plunkett, W., Hug, V., Keating, M. J., and Chubb, S. Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res., 40: 588-591, 1980.
33. Gandhi, V., Danhauser, L., and Plunkett, W. Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography. J. Chromatogr., 413: 293-299, 1987.
34. Sherman, P. A., and Fyfe, F. A. Enzymatic assay for deoxynuclecside triphosphates using synthetic oligonucleotides as template primers. Anal. Biochem., 180: 222-227, 1989.
35. Xie, C., and Plunkett, W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res., 55: 2847-2852, 1995.
36. Estey, E., Plunkett, W., Gandhi, V., Rios, M. B., Kantarjian, H., and Keating, M. J. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk. & Lymphoma, 9: 343-350, 1993.
37. Estey, E., Thall, P., Andreeff, M., Beran, M., Kantarjian, H., O'Brien, S., Escudier, S., Robertson, L. E., Koller, C., Komblau, S., Pierce, S., Freireich, E J., Deisseroth, A., and Keating, M. J. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol., 12: 671-678, 1994.
38. Chapman, A., Huang, P., Plunkett, W., and Gandhi, V. Consequences of incorporation of two nucleoside analogs into elongating DNA strands. Proc. Am. Assoc. Cancer Res., 35: 489, 1994.
39. Shewach, D. S., Ensminger, W. D., and Hughes, T. L. Apparent substrate inhibition of deoxycytidine kinase. Proc. Am. Assoc. Cancer Res., 35: 425, 1994.
40. Ross, D. D., Thompson, B. W., Jorieckis, C. C., Akman, S. A., and Schiffer, C. A. Metabolism of ara-C by blast cells from patients with ANLL. Blood, 68: 76-82, 1986.
41. Huang, P., Chubb, S., and Plunkett, W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. J. Biol. Chem., 205: 16617-16625, 1990.
42. Plunkett, W., and Gandhi, V. Cellular pharmacodynainics of anticancer drugs. Semin. Oncol., 20: 50-63, 1993.
43. Sato, J. K., Wiersma, S., Krallo, M., Bostrom, B., Shurin, S., Cheerva, A., Hammond, D., and Avramis, V. Phase I clinical and pharmacodynamic study of continuous infusion fludarabine followed by continuous infusion cytosine arabinoside in relapsed leukemia. Proc. Am. Assoc. Cancer Res., 33: 211, 1992.